passively removed by accompanying the solvent flow (convective transport) and consequently the solute concentration in the ultrafiltrate is equal to that in the water component of the plasma on the blood side of the membrane (1).
Vascular Access and Extracorporeal Pumps
Blood extracted from the patient after cannulation of a vessel, is moved through the extracorporeal circuit and then returned to the patient's circulation (1) . With some contemporary UF devices, a double lumen venous catheter is placed in the jugular or basilic vein allowing withdrawal and return of blood with minimal recirculation. Another type of UF device uses a single lumen needle for vascular access ( Figure 1 ). While the latter device allows cannulation of smaller veins, the highest blood flow, and therefore the maximum UF amount, is limited to about half of that obtainable from continuous flow devices (3, 4) . The rate and amount of ultrafiltrate produced depends on the TMP. In some devices, TMP is determined by the rate of blood flow through the hemofilter provided by a blood pump (1) . In other devices, production of ultrafiltrate can be increased or maintained at a lower blood flow by an ultrafiltrate pump which generates a negative pressure on the filtrate side of the hemofilter.
Clinical, Hemodynamic and Neurohormonal Effects of Extracorporeal Fluid Removal
The mechanisms by which mechanical fluid removal can restore diuretic responsiveness were explored in 32 HF patients (New York Heart Association class II-IV) with different degrees of fluid overload in whom neurohormones and renal perfusion pressure were measured during UF with the goal to reduce right atrial pressure by 50% (5) . Response to fluid removal revealed three phenotypes: 1) patients with refractory fluid overload and a daily urine output <1000 mL had a e 40% reduction in norepinephrine, plasma renin activity and aldosterone levels, a 16% increase in renal perfusion pressure, and a 493% increase in diuresis; 2) patients with a daily urine output >1000 mL had an increase in plasma renin activity of 40% and a decline in renal perfusion pressure by 12%; 3) patients without overt fluid excess and daily urine output >1000 mL had a 50% increase in neurohormone levels and a decline in renal perfusion pressure and urine output of 7% and 45%, respectively. An inverse correlation was observed between neurohormone levels and diuresis (P<0.0001) (5). Thus, depending on volume status, response to UF varies from neurohormonal downregulation and enhancement of sodium and water excretion to neurohormonal activation and oliguria. In a mechanistic study of the effects of UF performed in a clinical research unit, the benefits produced by UF in eight clinically stable HF patients did not occur in eight matched subjects treated with intravenous (IV) furosemide to achieve equivalent fluid removal (6) . In the latter group, norepinephrine, plasma renin activity, and aldosterone concentrations remained elevated above pre-treatment values for several days.
In contrast, in UF-treated patients a decrease in neurohormonal levels began 48 hours after therapy and was still detectable at 90 days (6) . The study's investigators hypothesized that the diverging longer-term responses may be related to lesser stimulation of renin secretion by UF compared to loop diuretics (6). In UF-treated patients, improvement in functional capacity (peak exercise oxygen consumption) persisted at 90 days (6) . Benefits were attributed to sustained reduction in lung water, which reduces lung stiffness, as indicated by concomitant improvement in spirometry values at rest and lung mechanics during exercise. There was also a reduction in heart size and in resting and exercise Doppler indices of hemodynamic restriction (7) . Fluid removal by UF was also accompanied by a decrease in right atrial and pulmonary capillary wedge pressures without reduction in cardiac output (7) (8) (9) (10) (11) . Although similar effects can be expected with any fluid removal therapy, the unpredictable net sodium loss with diuretics makes it difficult to document their sustained effects on cardiopulmonary interactions. Of interest, patients commonly experience an increase in urine output after treatment with UF. This may be due to the reduction in CVP and therefore in renal venous pressure and overall improvement in intra-renal hemodynamics once an adequate amount of fluid is removed. Similarly, diuretic resistant patients with high portal pressures due to cirrhosis exhibit increases in urine output when CVP and portal pressure are reduced by paracentesis or placement of a transjugular intrahepatic portosystemic shunt (12) . Thus, recovery of response to diuretics, due to systemic and renal hemodynamic improvements, may explain why the benefits of UF can persist beyond completion of therapy (5, 6, (8) (9) (10) (11) . This hypothesis could be tested using the newly proposed metrics of diuretic responsiveness described earlier (13).
Retrospective Cost-Analysis of Extracorporeal Ultrafiltration
The only study ever to evaluate the cost of UF in HF used a decision-analytic model to explore the clinical outcomes and associated costs of this therapy compared to IV diuretics for index and subsequent acute HF hospitalizations in 90 days (14) . Base-case probabilities and costs were derived from the UNLOAD trial, Medicare reimbursement schedules, and published data. The puzzling conclusions of this analysis were the following: from a societal (hospital) prospective UF had an 86% probability of being more expensive than IV diuretics (base-case estimate of $13,469 per UF patient vs. $11,610 per IV diuretic patient); from a Medicare payer perspective, UF had a > 99% probability of being cost saving. In addition to the intriguing definition of the hospital's, but not of Medicare's as the "societal" prospective, the conclusions of this costanalysis are based on incorrect assumptions: rates of bleeding, heparin-induced thrombocytopenia and catheter-related infections were obtained from the hemodialysis literature, where the incidence and severity of these complications are much higher than those associated with UF; the estimates were based on the use of each hemofilter for only 8 hours (an obsolete FDA restriction); the assumption that UF patients would always receive UF with each rehospitalization is simply untrue; the use of central venous access was overestimated; and the additional nursing costs were derived from the hemodialysis, not isolated UF claims (14) . These considerations underscore the need for new cost analyses based on contemporary UF therapy.
However, it is undeniable that isolated UF devices must be improved by the introduction of venous access and filters associated with a lower incidence of therapy-related complications and costs. 
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